Latest ESRD Stories

RIVER EDGE, N.J., Feb. 10, 2012 /PRNewswire/ -- Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that it will hold its 2012 Annual Meeting of Stockholders (the "Annual Meeting") at the Crowne Plaza Hotel, 401 South Van Brunt Street, Englewood, New Jersey, on April 23, 2012 at 10:00 a.m., Eastern Time. Additional information regarding...

An upward revision of the blood pressure numbers used to identify risk of end-stage renal disease (ESRD) might actually help doctors provide better care for their patients, said the authors of a study in patients with chronic kidney disease (CKD). The researchers found that systolic blood pressure – the “upper number” in a blood pressure reading – was the key variable. Current guidelines call for CKD patients to maintain a systolic pressure of 130/80 or lower in order to prevent...

Peritoneal dialysis and kidney transplantations lower among African-Americans, uninsured, and unemployed Newly published research shows that more patients with end-stage renal disease (ESRD) caused by lupus nephritis choose hemodialysis as their initial kidney replacement therapy over peritoneal dialysis and preemptive kidney transplantation. Results of the study now available in Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), also found that African...

LAWRENCE, Mass., Nov. 2, 2011 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Barry M. Straube, M.D., a member of its Board of Directors, was honored with the Mark Zawiski Memorial Award from the National Renal Administrators Association (NRAA). The award honors outstanding leadership in the End Stage Renal Disease (ESRD) community and was presented at the NRAA annual conference in New Orleans. (Logo:...

Urge the Committee to Ensure Kidney Failure Patients Covered Under the New Health Insurance Exchanges Will Have Same Choices as Patients Outside Exchanges WASHINGTON, Oct. 26, 2011 /PRNewswire-USNewswire/ -- In a letter to members of the Joint Select Committee on Deficit Reduction (Super Committee), the nation's leading kidney disease patient advocacy organizations urged the Super Committee to implement policy changes that would preserve health care coverage and access to care for kidney...

MENLO PARK, Calif. and SEATTLE, Oct. 3, 2011 /PRNewswire/ -- Frazier Healthcare and New Enterprise Associates (NEA) today announced a partnership to acquire 30 dialysis clinics from DaVita and DSI Renal. The resulting new platform company, DSI, will focus on delivering the highest quality of care for patients suffering from chronic kidney failure or end stage renal disease ("ESRD"). The company is co-founded by industry veterans Robert Lefton and Craig Goguen, who will serve as Executive...

NEW YORK, Sept. 19, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) today announced completion of patient enrollment in the long-term study component of its Phase 3 registration program of Zerenex(TM), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. The Zerenex Phase 3 registration program, which is being conducted pursuant to a Special...

Even though overall black patients have a lower risk of death while receiving dialysis than white patients, this applies primarily to older adults, as black patients younger than 50 years of age have a significantly higher risk of death, according to a study in the August 10 issue of JAMA."Of more than 500,000 individuals with end-stage renal disease (ESRD) in the United States, approximately one-third are black, and the relative incidence of ESRD is 3.6 times higher among black than...

(Ivanhoe Newswire) -- Researchers have recently published some promising results of a clinical study using an experimental anti-fibrotic and anti-inflammatory drug called pirfenidone to treat patients with diabetic nephropathy.Diabetes has become the most common single cause of end-stage renal disease (ESRD) in the U.S. and Europe due to the facts that 1) diabetes, particularly type 2, is increasing in prevalence; 2) diabetes patients now live longer; and 3) patients with diabetic ESRD are...

Patients with both type 1 diabetes and CKD have an increased risk of adverse outcomes. Despite aggressive treatment, many patients with type 1 diabetes and overt nephropathy develop End-Stage Renal Disease (ESRD) and/or succumb to a premature death. The competing risks of death and ESRD may confound the estimates of risk for each outcome.Now, the researchers at the University of Helsinki, University Hospital of Helsinki and Folkhälsan Research Center, Finland, and at the Queen Elisabeth...